In contrast, the nectin-4 expression rates were 45% in 20 PTC-origin ATC cases, 22% in 9 FTC-origin ATC cases, and 84% in 25 de novo ATC cases. This evidence concerns the gene NECTIN4 and thyroid cancer, nonmedullary, 2.